BioStock: Cereno's CEO on being granted "Compassionate Use"

Cereno Scientific has been granted Expanded Access by the FDA for drug candidate CS1 in rare disease pulmonary arterial hypertension. This will ensure that patients who have completed the ongoing phase II clinical study in PAH will have continued access to the drug. Cereno's CEO Sten R. Sörensen dropped by the BioStock Studio to talk about the importance of this decision.

Watch the interview with Sten R. Sörensen at biostock.se:

Cereno's CEO on being granted "Compassionate Use" - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/